Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
[Adjuvant endocrine therapy in breast cancer].
Huober J, Thürlimann B. Huober J, et al. Ther Umsch. 2008 Apr;65(4):193-200. doi: 10.1024/0040-5930.65.4.193. Ther Umsch. 2008. PMID: 18622910 Review. German.
[New treatment approaches in breast cancer].
Spirig C, Thürlimann B, Huober J. Spirig C, et al. Among authors: huober j. Ther Umsch. 2008 Apr;65(4):207-10. doi: 10.1024/0040-5930.65.4.207. Ther Umsch. 2008. PMID: 18622912 German.
Adjuvant! When the new world meets the old world.
Huober J, Thürlimann B. Huober J, et al. Lancet Oncol. 2009 Nov;10(11):1028-9. doi: 10.1016/S1470-2045(09)70323-7. Lancet Oncol. 2009. PMID: 19880058 No abstract available.
Bone targeted therapy in breast cancer: present and future.
Huober J, Thürlimann B. Huober J, et al. Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S7-10. doi: 10.1016/S1040-8428(10)70004-4. Crit Rev Oncol Hematol. 2010. PMID: 20427030 Review. No abstract available.
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: huober j. Ann Oncol. 2011 Jan;22(1):80-85. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1. Ann Oncol. 2011. PMID: 20595448 Free article. Clinical Trial.
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Zaman K, et al. Among authors: huober j. Ann Oncol. 2012 Jun;23(6):1474-81. doi: 10.1093/annonc/mdr448. Epub 2011 Oct 14. Ann Oncol. 2012. PMID: 22003243 Free article.
288 results